[Skip to Content]
[Skip to Content Landing]
February 15, 2006


Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;295(7):756-758. doi:10.1001/jama.295.7.756

To the Editor: The article by Dr Lanfear and colleagues1 highlights the importance of detailed mechanistic studies examining common single nucleotide polymorphisms to determine phenotypic differences that may have clinically significant implications. The authors note that β-blockade has been shown to reduce all-cause mortality after myocardial infarction. Their study showed that patients with an acute coronary syndrome who had the arginine allele (A) at nucleotide 46 of the β2-adrenergic receptor (ADRB2) had significantly greater incidence of mortality than patients with the glycine (G) allele at this position following hospital discharge with prescribed β-blockers.